Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Lakshminarayana, Suresh B ^a   Boshoff, Helena I M ^b   Cherian, Joseph ^a,d   Ravindran, Sindhu ^a,e   Goh, Anne ^a   Jiricek, Jan ^a   Nanjundappa, Mahesh ^a   Nayyar, Amit ^b,f   Gurumurthy, Meera ^a,g   Singh, Ramandeep ^b,f   Dick, Thomas ^a,g   Blasco, Francesca ^a   Barry III, Clifton E ^b   Ho, Paul C ^c   Manjunatha, Ujjini H ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Agency for Science   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^f AMRI Singapore Research Center ^*  (India)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE DERIVATIVE; AMINO 824; AMINOETHYL 824; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 135; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 136; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 145; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 147; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 176; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 182; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 269; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 297; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 302; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 622; BICYCLIC 4 NITROIMIDAZOLE DERIVATIVE 644; PRETOMANID; UNCLASSIFIED DRUG; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; 4-NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; RETROSPECTIVE STUDY; ANIMAL; CACO 2 CELL LINE; DISEASE MODEL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR CELL LINE;

ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; RETROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 84927585975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105222     Document Type: Article

References (76)

1. WHO (2012) Global Tuberculosis Report. World Health Organization, Geneva, Switzerland. www.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf.
2. WHO (2012) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. Report no.: WHO/HTM/TB/2010.3.
3. Balganesh TS, Alzari PM, Cole ST (2008) Rising standards for tuberculosis drug development. Trends Pharmacol Sci 29: 576-581. S0165-6147(08)00181-8 [pii];10.1016/j.tips.2008.08.001 [doi].
4. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. 10.1038/35016103 [doi]. (Pubitemid 30435054)
5. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466. 06-PLME-RA-0146R3 [pii];10.1371/journal.pmed.0030466 [doi].
6. Kaneko T, Cooper C, Mdluli K (2011) Challenges and opportunities in developing novel drugs for TB. Future Med Chem 3: 1373-1400. 10.4155/fmc.11.115 [doi].
7. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, et al. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294-2301. 49/6/2294 [pii];10.1128/AAC.49.6. 2294-2301.2005 [doi].
8. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, et al. (2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49: 2289-2293. 49/6/2289 [pii];10.1128/AAC.49.6.2289-2293.2005 [doi].
9. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK (2009) Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 53: 3720-3725. AAC.00106-09 [pii];10.1128/AAC.00106- 09 [doi].
10. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, et al. (2010) Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54: 3402-3407. AAC.01354-09 [pii];10.1128/AAC.01354-09 [doi].
11. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, et al. (2011) PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 239-245. AAC.00849-10 [pii];10.1128/AAC.00849-10 [doi].
12. Diacon AH, Dawson R, du BJ, Narunsky K, Venter A, et al. (2012) A phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. AAC.06125-11 [pii];10.1128/AAC.06125-11 [doi].
13. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, et al. (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380: 986-993. S0140-6736(12)61080-0 [pii];10.1016/S0140-6736(12)61080-0 [doi].
14. Barry CE, Cherian, J, Chio, I, Keller, T, Manjunatha UH, et al. (7-21-2011) Organic compounds. US Patent WO 2011/087995. United States patent application.
15. Blaser A, Palmer BD, Sutherland HS, Kmentova I, Franzblau SG, et al. (2012) Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b][1, 3]oxazine (PA-824). J Med Chem 55: 312-326. 10.1021/jm2012276 [doi].
16. Cherian J, Choi I, Nayyar A, Manjunatha UH, Mukherjee T, et al. (2011) Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H- imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybe nzyl)amine (6-amino PA-824). J Med Chem 54: 5639-5659. 10.1021/jm1010644 [doi].
17. Denny WA, Palmer BD (2010) The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future Med Chem 2: 1295-1304. 10.4155/fmc.10.207 [doi].
18. Jiricek J, Patel S, Keller T, Barry CE, Dowd CS, inventors; (5-7-2007) Nitroimidazole compounds. US Patent WO 2007/075872. United States patent application.
19. Kim P, Zhang L, Manjunatha UH, Singh R, Patel S, et al. (2009) Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem 52: 1317-1328. 10.1021/jm801246z [doi];10.1021/jm801246z [pii].
20. Kim P, Kang S, Boshoff HI, Jiricek J, Collins M, et al. (2009) Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J Med Chem 52: 1329-1344. 10.1021/jm801374t [doi];10.1021/ jm801374t [pii].
21. Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, et al. (2010) Synthesis and Structure-Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1, 3]oxazine (PA-824). J Med Chem. 10.1021/jm101288t [doi].
22. Palmer BD, Thompson AM, Sutherland HS, Blaser A, Kmentova I, et al. (2010) Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2,1-b][1, 3]oxazine (PA-824). J Med Chem 53: 282-294. 10.1021/jm901207n [doi].
23. Thompson AM, Sutherland HS, Palmer BD, Kmentova I, Blaser A, et al. (2011) Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1, 3]oxazine (PA-824). J Med Chem 54: 6563-6585. 10.1021/jm200377r [doi].
24. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, et al. (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 431-436. 0508392103 [pii];10.1073/pnas.0508392103 [doi].
25. Zhou L, Yang L, Tilton S, Wang J (2007) Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J Pharm Sci 96: 3052-3071. 10.1002/jps.20913 [doi]. (Pubitemid 350221202)
26. Wohnsland F, Faller B (2001) High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44: 923-930. jm001020e [pii].
27. Avdeef A, Bendels S, Di L, Faller B, Kansy M, et al. (2007) PAMPA-critical factors for better predictions of absorption. J Pharm Sci 96: 2893-2909. 10.1002/jps.21068 [doi]. (Pubitemid 350221191)
28. Marino AM, Yarde M, Patel H, Chong S, Balimane PV (2005) Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int J Pharm 297: 235-241. S0378-5173(05)00186-9 [pii];10.1016/j.ijpharm.2005.03.008 [doi].
29. Fung EN, Chen YH, Lau YY (2003) Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795: 187-194. S1570023203005646 [pii].
30. Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, et al. (2013) Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med 5: 214ra168. 5/214/214ra168 [pii];10.1126/scitranslmed.3007355 [doi].
31. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, et al. (2002) Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 17: 1987-1993.
32. Djukic M, Munz M, Sorgel F, Holzgrabe U, Eiffert H, et al. (2012) Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid. Antimicrob Agents Chemother 56: 979-988. AAC.00437-11 [pii];10.1128/AAC.00437-11 [doi].
33. Ferl GZ, Zhang X, Wu HM, Kreissl MC, Huang SC (2007) Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med 48: 2037-2045. jnumed.107.041061 [pii];10.2967/jnumed.107.041061 [doi].
34. Stella VJ, Rajewski RA (1997) Cyclodextrins: their future in drug formulation and delivery. Pharm Res 14: 556-567. (Pubitemid 27220271)
35. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118-2124. (Pubitemid 36753560)
36. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, et al. (2004) Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48: 2951-2957. 10.1128/AAC.48.8.2951- 2957.2004 [doi];48/8/2951 [pii].
37. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, et al. (2007) Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51: 576-582. AAC.00414-06 [pii];10.1128/AAC.00414-06 [doi].
38. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, et al. (2012) Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 1444-1451. AAC.00720-11 [pii];10.1128/AAC.00720-11 [doi].
39. Burman W, Dooley KE, Nuermberger EL (2011) The Rifamycins: Renewed Interest in an Old Drug Class. Chapter 3 Donald RP, Van Helden PD (eds): Antituberculosis Chemotherapy. Prog Respir Res. Basel, Karger. 40. 40: 18-24.
40. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, et al. (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56: 4331-4340. AAC.00912-12 [pii];10.1128/AAC.00912-12 [doi].
41. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, et al. (2011) Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 15: 305-316.
42. van IJ, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, et al. (2011) Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis 52: e194-e199. cir184 [pii];10.1093/cid/cir184 [doi].
43. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395. 322/5906/1392 [pii];10.1126/science.1164571 [doi].
44. Obach RS, Lombardo F, Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405. dmd.108.020479 [pii];10.1124/dmd.108.020479 [doi].
45. Veber B, Vallee E, Desmonts JM, Pocidalo JJ, Azoulay-Dupuis E (1993) Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. J Antimicrob Chemother 32: 473-482. (Pubitemid 23295294)
46. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, et al. (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 43 Suppl B: 69-76.
47. Siefert HM, Kohlsdorfer C, Steinke W, Witt A (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 43 Suppl B: 61-67.
48. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, et al. (2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421-426. 10.1164/rccm.200310-1380OC [doi];200310-1380OC [pii].
49. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, et al. (2011) High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83: 2112-2118. 10.1021/ac1029049 [doi].
50. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227. 1106753 [pii];10.1126/science.1106753 [doi].
51. Barbour A, Scaglione F, Derendorf H (2010) Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/ pharmacodynamic indices. Int J Antimicrob Agents 35: 431-438. S0924-8579(10)00068-3 [pii];10.1016/j.ijantimicag.2010.01.023 [doi].
52. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10.
53. Craig WA (2001) Does the dose matter? Clin Infect Dis 33 Suppl 3: S233-S237. CID001113 [pii];10.1086/321854 [doi].
54. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19: 261-268. S0924857902000225 [pii].
55. Scaglione F, Paraboni L (2006) Influence of pharmacokinetics/ pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 4: 479-490. 10.1586/14787210.4.3.479 [doi]. (Pubitemid 43905469)
56. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, et al. (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50: 2621-2625. 50/8/2621 [pii];10.1128/AAC.00451-06 [doi].
57. Lin JH (2006) Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 7: 39-65.
58. Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9: 929-939. nrd3287 [pii];10.1038/nrd3287 [doi].
59. Gonzalez D, Schmidt S, Derendorf H (2013) Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26: 274-288. 26/2/274 [pii];10.1128/CMR.00092-12 [doi].
60. Liu P, Muller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19: 285-290. S0924857902000249 [pii].
61. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, et al. (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61: 235-237. dkm476 [pii];10.1093/jac/dkm476 [doi].
62. Muller M, dela PA, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 48: 1441-1453.
63. Theuretzbacher U (2007) Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 7: 498-504. S1471-4892(07)00096-3 [pii];10.1016/j.coph.2007.05.003 [doi].
64. Brunner M, Derendorf H, Muller M (2005) Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 5: 495-499. S1471-4892(05)00106-2 [pii];10.1016/j.coph.2005.04. 010 [doi].
65. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, et al. (2007) AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24: 1014-1025. 10.1007/s11095-006-9206-z [doi]. (Pubitemid 46675390)
66. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG (2002) Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 50: 1011-1015. (Pubitemid 36032825)
67. Conte JE Jr., Golden JA, McQuitty M, Kipps J, Duncan S, et al. (2002) Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother 46: 2358-2364. (Pubitemid 34793436)
68. Conte JE Jr., Golden JA, Kipps J, Lin ET, Zurlinden E (2001) Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob Agents Chemother 45: 2891-2896. 10.1128/AAC.45.10. 2891-2896.2001 [doi]. (Pubitemid 32906688)
69. Conte JE Jr., Golden JA, Duncan S, McKenna E, Zurlinden E (1999) Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 43: 1329-1333. (Pubitemid 29259320)
70. Conte JE Jr, Golden JA, McQuitty M, Kipps J, Lin ET, et al. (2000) Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Antimicrob Agents Chemother 44: 985-990. (Pubitemid 30165280)
71. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R (1999) Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 44: 835-838.
72. Chierakul N, Klomsawat D, Chulavatnatol S, Chindavijak B (2001) Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis. Int J Tuberc Lung Dis 5: 278-282. (Pubitemid 32397607)
73. Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46: 1475-1480. (Pubitemid 34415331)
74. Kiem S, Schentag JJ (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52: 24-36. AAC.00133-06 [pii];10.1128/AAC.00133-06 [doi].
75. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, et al. (2012) Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56: 446-457. AAC.05208-11 [pii];10.1128/AAC.05208-11 [doi].
76. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, et al. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1: 57. ncomms1060 [pii];10.1038/ncomms1060 [doi].